Genaera Corp

Genaera — Technical Presentation (August 2007)

37 slides from Genaera's technical presentation, Aug 9, 2007

  1. Slide 1: Trodusquemine - A Novel Aminosterol for the Treatment of Obesity

    Trodusquemine - A Novel Aminosterol for the Treatment of Obesity and Related Metabolic Disorders Case Studies: Moving a Compound from Discovery to Preclinical to Proof-of-Concept Boston, MA August 8, 2007 Anthony DelConte, MD Vice President, Clinical R & D Exhibit 99.2

  2. Slide 2: Trodusquemine (MSI-1436)

    Trodusquemine (MSI-1436) N H N H N H O H OH S O OH O N H

  3. Slide 3: Obesity Comorbidities

    Pulmonary disease Pulmonary disease abnormal function abnormal function obstructive sleep apnea obstructive sleep apnea hypoventilation syndrome hypoventilation syndrome Nonalcoholic fatty liver Nonalcoholic fatty liver disease disease steatosis steatosis steatohepatitis steatohepatitis cirrhosis ci

  4. Slide 4: Unmet Medical Needs - Obesity

    Unmet Medical Needs - Obesity • Current Therapies (US) – Phentermine – short term – Sibutramine – Orlistat – Rimonobant (withdrawn after June 13 FDA mtg) • Over 300 Drugs in Development – 42 Phase I-III 38 different MOAs (12% DA, 8% CB1) Source: Datamonitor 2006

  5. Slide 5: History of Trodusquemine Development

    History of Trodusquemine Development • Aminosterol ( Squalus acanthias ) – Fully synthetic process • Animals Experience Weight Loss • Serendipity • Development as an Obesity Therapy

  6. Slide 6: (SGENAERA

    (SGENAERA

  7. Slide 7: Inhibitor Specificity Difficult Due to High Homology Between PTP-1B and TC-PTP

    Inhibitor Specificity Difficult Due to High Homology Between PTP-1B and TC-PTP Iversen, L. F. et al. J. Biol. Chem. 2002;277:19982-19990 PTP-1B TC-PTP

  8. Slide 8: A Selective PTP-1B Inhibitor

    A Selective PTP-1B Inhibitor MSI-1436 is highly selective for PTP-1B relative to TC - PTP -8 -7 -6 -5 -4 -3 -2 PTP1B TCPTP MSI-1436 log (M) 224 µM TC-PTP 1 µM PTP-1B IC Enzyme 224 µM TC-PTP 1 µM PTP-1B IC Enzyme

  9. Slide 9: MSI-1436 is an Allosteric, Noncompetitive Inhibitor of PTP-1B

    MSI-1436 is an Allosteric, Noncompetitive Inhibitor of PTP-1B 149.33 7.60 425.34 36.40 V max uM pNP/min/ug of protein 3.63 0.30 pNPP + MSI 1436 2.25 0.40 pNPP K m (mM) Experiment 149.33 7.60 425.34 36.40 V max uM pNP/min/ug of protein 3.63 0.30 pNPP + MSI 1436 2.25 0.40 pNPP K m (mM) Experiment pNPP

  10. Slide 10: MSI-1436 Inhibits PTP-1B in Cell Based Assay

    30 minutes 3 hours IR IR IP, P-Tyr IR IR IP, P-Tyr HepG2 cells MSI-1436 Inhibits PTP-1B in Cell Based Assay X X X X Trodusquemine X X X X Insulin X X X X Trodusquemine X X X X Insulin 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 Trodusquemine Induces IR Phosphorylation

  11. Slide 11: PTP-1B Target Validation

    Body Wt Appetite Fatty Acid Oxidation Leptin Sensitivity Insulin Sensitivity 1436 (DIO mice) Brain-Specific KO Brain-specific PTP-1B Knock-Out mimics MSI-1436 induced weight loss PTP-1B Target Validation Bence, et al, Nature Med, 12(8): 917-924 (2006) Central Effect - Obesity Body Wt Appetite Fatty

  12. Slide 12: MSI-1436 Induces Central c-fos Activity

    MSI-1436 Induces Central c-fos Activity R. Ahima et al, Diabetes , 51:2099-2014, 2002 Vehicle MSI-1436 c-fos indicates neural activity

  13. Slide 13: Establishing Preclinical Efficacy

    Establishing Preclinical Efficacy

  14. Slide 14: MSI-1436 Induced Weight Loss in Multiple Obesity Models

    • ob/ob mouse • db/db mouse • Diet-induced obese (DIO) mouse • Zucker fa/fa rat MSI-1436 Induced Weight Loss in Multiple Obesity Models:

  15. Slide 15: MSI-1436 Induced Weight Loss

    MSI-1436 Induced Weight Loss -80 -60 -40 -20 Day of Study Vehicle MSI-1436 (5 mg/kg) (ob/ob Mouse Model) 151% - 61%

  16. Slide 16: MSI-1436 in DIO Model

    Control Diet 60% Fat Diet MSI-1436 in DIO Model Dosing Schedule Day 0 - 10 mg/kg Day 7 - 5 mg/kg Day 14 – 5 mg/kg Day 21 – 5 mg/kg • Proportional to pre-treatment body weight • Weight lost is all fat • No muscle loss Treatment Period Fattening Period 14% 37% 41% Weight Loss 45% Fat Diet Time (Days)

  17. Slide 17: MSI-1436 Impact on Adipose

    White Adipose Tissue Brown Adipose Tissue 60% fat diet, Saline 60% fat diet, Trodusquemine MSI-1436 Impact on Adipose Dramatic, Visual Decrease in Stored Fat

  18. Slide 18: MSI-1436 and Rebound

    MSI-1436 and Rebound -50 -40 -30 -20 -10 Study Day 60% diet, Trodusquemine 60% diet, Pair-fed Resists Change in Metabolic Set Point

  19. Slide 19: MSI-1436 and Type 2 Diabetes

    MSI-1436 and Type 2 Diabetes Takahashi, et al, J. Hepatology, 41: 391-398 (2004) Improves Insulin Sensitivity (Independent of weight loss) Saline Pair-Fed MSI-1436 Wild type mice Lowers Blood Glucose Single 1436 dose at t-1 day Insulin bolus at t = 0 Ob/Ob mice Multiple 1436 doses 8 mg/kg (q4 days x

  20. Slide 20: MSI-1436 and Dyslipidemia

    MSI-1436 and Dyslipidemia Lowers Serum Cholesterol Lowers Serum Triglycerides 95.4 78.2 Ob/Ob Pair-fed Ob/Ob Saline Ob/Ob MSI-1436 Wild-type saline 0.1 0.31 3.1 MSI-1436, mg/kg/week M. Zasloff et al Intl J Obesity 25: 689-697, 2001

  21. Slide 21: Establish Preclinical Safety: Toxicology

    Establish Preclinical Safety Toxicology

  22. Slide 22: MSI-1436 (Trodusquemine) Completed Studies by Type

    MSI-1436 (Trodusquemine) MSI-1436 (Trodusquemine) Completed Studies by Type Completed Studies by Type • • Genetic Toxicity : Genetic Toxicity : Bacterial mutation (Ames Bacterial mutation (Ames test), in vitro test), in vitro (CHO) and in vivo (CHO) and in vivo (mouse (mouse micronucleus) chromosoma

  23. Slide 23: First-in-Human

    First-in-Human IND Filed March 2007 First Subject Dosed May 17th

  24. Slide 24: Phase I Study Overview

    Phase I Study Overview • To evaluate the safety and tolerance of ascending single IV doses of MSI-1436 • To evaluate pharmacokinetics (PK) of MSI-1436 • Healthy overweight or obese male and female subjects – 18 to 55 years of age – BMI of 27-40 kg/m2

  25. Slide 25: MSI-1436 Study Design

    MSI-1436 101 Study Design • Double blind, randomized, placebo- controlled • 7 subjects per group enrolled in sequential dose groups • 5 subjects receive MSI-1436 and 2 subjects receive vehicle in each dose group

  26. Slide 26: Study Design

    Study Design • 3 week screening • Admitted on Day –1 and to remain in house for 4 nights • Return on Days 7,14, & 21 for follow-up • Vital signs • Clinical laboratories • PK sample collections • Day 21, all end-of-study evaluations

  27. Slide 27: Inclusion/Exclusion Criteria

    Inclusion/Exclusion Criteria • Inclusion – Healthy male or female subjects, between 18 and 55 years old – Non-smokers - (Cotinine levels <200 ng/mL) – BMI of 27- 40 kg/m • Exclusion – Clinically significant disease history – Abnormal vital signs, PE, labs, or any safety variable – Requires treatment

  28. Slide 28: Pharmacokinetics of MSI-1436

    Pharmacokinetics of MSI-1436 Time (hours) Cohort (0.3 mg/m ) Cohort (1 mg/m ) Cohort (3 mg/m ) Cohort (10 mg/m )

  29. Slide 29: AUC (inf)

    AUC{inf) (ug*himL) 28) 100 10 a4 0.01 ° Individual Mean - Median 1 1 Dose {mgim”) 10 ©'GENAERA

  30. Slide 30: Cmax

    Cmax (ug/mL) a4 o.01 30 i} Individual Mean Median a4 1 Dose (mgim’) 10 ©'GENAERA

  31. Slide 31: Adverse Events (Drug & Vehicle)

    Adverse Events (Drug & Vehicle) • No Serious AEs Reported • 19 Subjects reported 44 AEs – 38 grade 1 – 6 grade 2 • 9 subjects had no AEs • 23 occurred within 24 hours of dosing • 16 occurred 2 or more days after dosing

  32. Slide 32: Adverse Events

    Adverse Events • There were no discontinuations due to AEs • No safety signals, profile consistent with placebo (vehicle) • Plan to continue until dose limiting toxicity is established

  33. Slide 33: Conclusions

    Conclusions • Trodusquemine is a centrally acting, selective PTP-1B inhibitor in Phase I development • Preclinical efficacy has been demonstrated in multiple diet induced and transgenic models of obesity • Although pursued for over a decade, PTP-1B as a target has defied rational drug design strateg

  34. Slide 34: Back-up Slides

    Back-up Slides

  35. Slide 35: (GENAERA

    (GENAERA

  36. Slide 36: (GENAERA

    (GENAERA

  37. Slide 37: MSI-1436 Reduces Body Fat in DIO Mouse Model

    Vehicle MSI-1436 Vehicle MSI-1436 Vehicle MSI-1436 MSI-1436 Reduces Body Fat 10% Fat Diet 60% Fat Diet 45% Fat Diet p < 0.001 p < 0.001 p < 0.001 in DIO Mouse Model

Genaera — Technical Presentation (August 2007) on 6ix